New PET tracer aims to light up hidden artery plaques
NCT ID NCT07815860
First seen Sep 11, 2026 · Last updated Sep 11, 2026
Summary
Researchers are testing an experimental PET imaging tracer called 18F-S2P to see how well it detects inflamed plaques in people with large-artery atherosclerosis. About 200 adults aged 40 to 80 with suspected atherosclerosis receive an intravenous dose of the tracer and then undergo a PET/CT scan. The study compares the tracer's performance with standard imaging such as carotid ultrasound and magnetic resonance angiography.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an experimental PET imaging tracer called 18F-S2P
- What this could lead to
- If it works, doctors could gain a sharper way to find inflamed plaques that raise the risk of stroke or heart attack, helping them target treatment earlier.
- What could go wrong
- This is an early imaging study, so the tracer may not light up plaques reliably or may miss some that other scans catch. It also involves radiation exposure and requires lying still inside a scanner.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Aged 40 to 80 years old; 2. Clinically suspected large artery atherosclerosis; 3. Able to understand and comply with all study requirements; 4. Participants aged ≥65 years with full civil capacity may sign informed consent independently; those with limited civil capacity shall sign the informed consent together with their legal guardians. Exclusion Criteria 1. Pregnant or breastfeeding female patients; 2. Patients with severe claustrophobia, radiophobia, mental disorders or primary emotional disorders; 3. Abnormal laboratory indicators at screening: hemoglobin (Hb) \<10 g/dL, white blood cell (WBC) \<3×10\^9/L, platelet (PLT) \<90×10\^9/L, or creatinine clearance (CrCl) \<40 mL/min; 4. Subjects received ionizing radiation outside this trial within the past year leading to an annual radiation exposure exceeding 50 mSv; 5. Subjects received any investigational drugs or devices with unconfirmed safety/efficacy within one month before enrollment; 6. Any condition judged by the principal investigator that may bring potential harm to participants during the trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Large-artery atherosclerosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.